Ringgaardvaldez1875

BACKGROUND/AIM Differences in risk factors for melanoma between young adults (18-39 years) and middle-aged (40-60 years) are not well documented. In this study, we aimed to determine differences in risk factors and characteristics of melanoma between these groups. PATIENTS AND METHODS This retrospective study is a review on 330 patients, including 250 middle-aged and 80 young adults, during the period 2006-2016 in the Tampere university hospital, in Finland. RESULTS Forty-one per cent of middle-aged and 47% of young adults were defined as higher-risk patients. High nevus count was the most common host risk factor in both groups. Young were more likely to have a family history of melanoma. Middle-aged had more often excessive intermittent sun exposure and a history of sunburn. Host risk characteristics were less commonly associated with thicker melanomas. CONCLUSION A high number of patients have host risk factors for melanoma. Several differences exist in risk factors and characteristics of melanomas between young adults and middle-aged patients. BACKGROUND Leiomyomas are common in women of reproductive age, for whom treatment-stratification can be challenging. We assessed factors influencing pre-operative selection of surgical intervention and compare outcomes. PATIENTS AND METHODS A literature review was performed and surgical interventions for fibroids at a London hospital (2015-2018) were retrospectively examined. Outcomes assessed were estimated blood loss, length of stay (LOS) and complications. Data were analysed using univariate non-parametric inferential statistics. RESULTS A total of 258 cases were identified. Estimated blood loss was statistically significantly lower for laparoscopic versus open myomectomy [200 (interquartile range; IQR)=100-200 vs. 400 (IQR=200-700 ml), p less then 0.001]. Length of stay was also statistically significantly lower in the laparoscopic cohort compared with open hysterectomy [1 (IQR=1-1) days vs. 2 (IQR=2-3 days)]. Similar results were noted when comparing laparoscopic versus open hysterectomy [167 (IQR=100-200) vs. 500 (IQR=100-750) ml, p less then 0.001]. No differences in complications were reported across groups. Patients counselled by a surgeon trained in minimally invasive surgery (MIS) opted more frequently for laparoscopy (p less then 0.01, rho=-0.669). Estimated blood loss during MIS was 225 ml versus 545 ml for non-MIS, and 285 ml for the overall cohort (p less then 0.01).The length of stay was statistically significantly lower for those treated with MIS (1.37 days) versus other surgeons (2.65 days), or overall cohort (1.63 days) (p less then 0.01 for all associations). CONCLUSION Laparoscopic surgery offers superior short-term outcomes when performed by experienced operators. Multidisciplinary counselling and treatment stratification should be gold-standard practice. Centralisation of care provision in fibroid Centres of Excellence is required. BACKGROUND/AIM The bioimpedance analysis (BIA) can provide anthropometric data on patients. The aim of the study is to evaluate the clinical relevance of these automatically obtained values. PATIENTS AND METHODS We studied the arm circumference (AC) and arm muscle circumference (AMC) of 197 histologically proven cirrhotic patients. The BIA-based anthropometric data were compared to the manually measured data. In addition, we evaluated whether or not the BIA-based anthropometric data were associated with the prognosis of the patients. RESULTS The data of %AC and %AMC obtained using the two methods were well correlated (p less then 0.001) with relatively inconspicuous differences (approximately 6.0% for %AC and 16.0% for %AMC). The data of %AC and %AMC obtained from the BIA method were significantly associated with the prognosis of the patients. CONCLUSION The BIA-based anthropometric data were associated with the direct measurement data and related to the prognosis of cirrhotic patients. AIM to assess efficacy and safety of chemoembolization alone (TACE) and followed by bevacizumab (TACE-B) in patients with colorectal liver metastases (CRC-LM) (NCT03732235). PATIENTS AND METHODS The study included 30 consecutive patients with CRC-LM. They were informed about the types of treatment available TACE with irinotecan loaded into polythylene glycol embolics alone or followed by bevacizumab therapy. Endoxifen supplier Each patient underwent self-randomization and 17 chose TACE, whereas 13 chose TACE-B. RESULTS Tumor response at 3 months was complete response in one (6%) and four (31%) patients, and partial response in two (13%) and six (46%) patients, after TACE and TACE-B, respectively. No complications were observed during TACE. Most TACE-related adverse events were correlated with post-embolic syndrome. CONCLUSION The preliminary results of the study showed that the TACE-B is feasible and tolerable. This study will be continued in order accrue a larger number of patients and longer follow-up. BACKGROUND/AIM Understanding prognostic factors of survival are important for treatment personalization in cancer patients. This study aimed to identify such factors for patients irradiated for bone metastases from prostate cancer. PATIENTS AND METHODS Data from 74 patients irradiated between 01/2009 and 04/2019 were retrospectively evaluated. Ten characteristics were investigated for survival. RESULTS Median survival in the entire cohort was 12 months. Survival rates at 3, 6, 9 and 12 months were 84%, 73%, 56% and 47%, respectively. On univariate analyses, the Eastern Cooperative Oncology Group (ECOG) performance score of 0-1 was associated with improved survival (p less then 0.001), absence of visceral metastases (p=0.099) and only one irradiated metastatic site (p=0.099) showed a trend. On Cox regression analysis, only ECOG performance score (risk ratio=3.58, p less then 0.001) was significant. CONCLUSION ECOG performance score is an independent prognostic factor of survival after irradiation of bone metastases from prostate cancer and may allow better personalization of care. BACKGROUND/AIM Previous research has suggested that patients with metastatic renal cell cancer (mRCC) and bone metastases have a poorer prognosis compared to their counterparts with no skeletal involvement. Therefore, we analyzed the management and outcomes of such patients in our center. PATIENTS AND METHODS We performed a retrospective study of 35 consecutive patients who received systemic treatment, largely targeted therapy, for mRCC with bone metastases. RESULTS The median overall survival was 25 months from the time of diagnosis of mRCC. The 5-year survival rate was 16%. Survival from diagnosis of mRCC was significantly worse in patients with bone metastases present at the start of first-line systemic therapy (median 13 months) compared to delayed metastases diagnosed later during the course of disease (46 months, p=0.01). Few patients (29%) were able to receive more than two lines of systemic therapy. Bone-only metastases were uncommon (11%). CONCLUSION Most patients with mRCC and bone metastases have limited overall survival.